Table 1.
Effect of variant and vaccination on emergency COVID-19 associated hospitalization or COVID-19 death for individuals sequenced in the community
Population characteristic | Total sequenced cases | Number of eventsa | Adjusted hazard ratio | 95% confidence interval | Person-years of exposure | |
---|---|---|---|---|---|---|
Sex | Female | 50,749 | 263 | Reference | NA | 3205.0 |
Male | 40,315 | 226 | 1.02 | 0.85–1.22 | 2566.0 | |
COVID-19 variant | BA.1 variant | 48,322 | 183 | Reference | NA | 3147.8 |
BA.2 variant | 23,325 | 67 | 0.84 | 0.60–1.18 | 1298.3 | |
Delta variant | 13,896 | 168 | 2.33 | 1.39–3.90 | 931.7 | |
Other variants | 5521 | 71 | 2.47 | 1.46–4.18 | 393.6 | |
Vaccination Statusb | No vaccination | 12,188 | 102 | Reference | NA | 772.5 |
One vaccine dose 0-27 days before test | 210 | 1 | 0.57 | 0.08–4.08 | 14.1 | |
One vaccine dose >28 days before test | 2751 | 17 | 0.85 | 0.51–1.42 | 174.2 | |
Two vaccine doses 0-27 days before test | 219 | 1 | 0.69 | 0.10–4.94 | 14.0 | |
Two vaccine doses >28 days before test | 27,977 | 167 | 0.47 | 0.36–0.61 | 1923.1 | |
Three vaccine doses 0-27 days before test | 6401 | 25 | 0.25 | 0.16–0.39 | 446.6 | |
Three vaccine doses >28 days before test | 41,318 | 176 | 0.52 | 0.39–0.70 | 2426.6 | |
Number of pre-existing conditionsc | No pre-existing Condition | NA | NA | Reference | NA | NA |
One condition | 55,672 | 182 | 1.86 | 1.50–2.32 | 3713.0 | |
Two conditions | 24,101 | 153 | 2.90 | 2.19–3.84 | 1540.0 | |
Three conditions | 7230 | 74 | 5.89 | 4.17–8.33 | 392.0 | |
Four conditions | 2397 | 47 | 6.68 | 4.05–11.04 | 90.0 | |
Five or more conditions | 993 | 19 | 10.02 | 5.58–18.00 | 26.0 | |
Scottish Index of Multiple Deprivation (SIMD) Quintile (2020) | 1 (lowest) | 671 | 14 | Reference | NA | 11.0 |
2 | 18,927 | 106 | 0.82 | 0.63–1.04 | 1185.0 | |
3 | 16,843 | 83 | 0.71 | 0.54–0.93 | 1062.0 | |
4 | 17,819 | 80 | 0.67 | 0.51–0.89 | 1136.0 | |
5 (highest) | 17,316 | 82 | 0.71 | 0.53–0.94 | 1136.0 |
Population characteristics shown in table comprise all covariates used in the Cox regression model. Effects are presented as adjusted hazard ratios and 95% confidence intervals compared to the reference baseline of symptomatic infection with BA.1.
COVID-19 associated hospitalization or death was defined as either (i) a hospital admission from the community flagged as an emergency with a positive RT-PCR test in the 14 days prior to admission, or within 2 days following admission, or (ii) death with COVID-19 listed as a cause of death on the death certificate or death within 28 days of a positive community RT-PCR test.
Vaccination status includes Oxford/AstraZeneca (ChAdOx1-S) vaccine, Moderna (mRNA-1273) vaccine, and Pfizer-BioNTech (BNT162b2) vaccines. See Table S1 for comparison of vaccine status.
Number of existing conditions was determined using the QCOVID algorithm risk groups.